Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism
Authors' conclusion
Semaglutide markedly improved sperm morphology, total testosterone levels and symptoms of hypogonadism. These findings highlight semaglutide's potential as a therapeutic approach for men with obesity-related FH who desire fertility.
Study context
- Population
- Men with T2D, obesity and functional hypogonadism (FH); aged 50 [46–60] years, BMI 35.9 [32.8–38.7] kg/m²
- Participants
- 25 men
- Comparison
- Semaglutide vs testosterone replacement therapy (TRT)
- Primary endpoint
- Semen quality and parameters of FH
- Follow-up
- 24 weeks
Methodological detailsopen-label
- Open-label
Primary result
As reported in the abstract
Morphologically normal sperm · baseline to 24 weeks
Semaglutide (SEMA): significant increase in morphologically normal sperm from baseline to end of study
2% [2; 3.5] vs. 4% [2; 5.5]
p = 0.012
Further findings
Baseline sperm parameters
- Poor quality, below the 5th percentile of reference values
Total testosterone and AMS score · 24 weeks
- Both groups: increase in total testosterone and improvement in AMS score
IIEF-15 score · 24 weeks
- Significantly improved only with TRT
Original publication
Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. Diabetes Obes Metab. Published 7 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →